Quarter ended on March 31, 2025Data in Crores of INR
Revenue₹ 57.79+88.92% from last year
Operating profits₹ 1.51+174.56% from last year
Net income₹ 0.70+156.77% from last year
Data is unavailable
Data is unavailable
View detailed balance sheet
Profitability ratios
ROA0.12%
ROE0.19%
ROCE-0.29%
EPS0.07%
Net profit margin0.18%
Operating profit margin0.7%
Dividend per share
Operational ratios Quick ratio7.41%
Current ratio7.76%
Interest coverage-8.89%
Assets turnover0.66%
Debt to equity0.32%
Valuation ratios P/E ratio
P/B ratio1.58%
Dividend yield
EV/EBITDA
Valiant Laboratories was originally formed as a partnership firm under the name and style of ‘M/s. Bharat Chemicals’ pursuant to the deed of partnership dated October 17, 1980, amended and restated from time to time. Subsequently, the partnership firm, M/s. Bharat Chemicals was converted into a public limited company under the provisions of the Companies Act with the name “Valiant Laboratories Limited” pursuant to certificate of incorporation dated August 16, 2021 issued by the by Central Registration Centre, Registrar of Companies.The company is an Active Pharmaceutical Ingredient (API) / Bulk Drug manufacturing company having focus on manufacturing of Paracetamol. Bulk drugs/Active Pharmaceutical Ingredients (API) serve as raw materials for manufacturing finished dosage forms or formulations. Paracetamol (Scientific name: Acetaminophen or para-hydroxyacetanilide - C8H9NO2), is one of the most commonly taken analgesic worldwide and is recommended as the first-line therapy in pain conditions by the World Health Organization (WHO). Paracetamol has several applications such as usage in treatment of headaches, muscle aches, arthritis, back aches, toothaches, cold and fever. The company manufacture Paracetamol in various grades such as IP/BP/EP/USP, as per the pharmacopeia requirements of its customers. Paracetamol was initially approved by the U.S. Food and Drug Administration (USFDA) in 1951 and is available in a variety of forms including syrup form, regular tablets, effervescent tablets, injection, suppository, and other forms. Paracetamol is often found combined with other drugs in many over the counter (OTC) allergy medications, cold medications, sleep medications, pain relievers, and other products.The company was originally formed in year 1980 as a partnership firm under the Indian Partnership Act, 1932 under the name and style of ‘Bharat Chemicals’ and gradually, commenced manufacturing of Paracetamol by late 1982. In August 2021, its partnership firm was converted into a public limited company registered under the Companies Act. Its manufacturing facility is located at Plot nos. L-13 and L-30, Tarapur Industrial Area, Boisar, Palghar, in the state of Maharashtra, India. The company’s Manufacturing Facility employs modern machinery and equipment to ensure smooth flow of operations. It is holding certificate of good manufacturing practices (GMP) for manufacture and sale of bulk drugs / API and ISO 9001:2015 certification. Its quality control team monitors the manufacturing process at all stages from initial testing stage for incoming raw material to the final product prior to packing.Business area of the companyValiant Laboratories is a leading Active Pharmaceutical ingredient manufacturing company with its focus on manufacturing Paracetamol API/Bulk Drug which has several applications like uses in treatment of conditions such as headache, muscle ache, arthritis, back ache, toothache, cold and fever.Key events and milestones1980: Formed Bharat Chemicals (a partnership firm).1981: Acquired plot No. L-30 in the Tarapur Industrial Area, Palghar, Maharashtra on leasehold basis admeasuring about 1,000 sq. mtrs.1982: Commenced manufacture of Paracetamol.2004-05: Acquired additional Plot Nos. L-28, L-28 (part), L-29 and L-13 at Tarapur Industrial Area, Palghar, Maharashtra collectively admeasuring about 3,000 sq. mtrs.2015: Annual revenue from operations crossed Rs 500 million.2021: Converted from partnership firm into a public limited company.2021: Annual revenue from operations crossed Rs 1,000 million.2022: Annual revenue from operations crossed Rs 2,000 million.2022: Formed wholly owned subsidiary, VASPL to diversify business activities.
Show figures in :
